SIBO is misdiagnosed as IBS routinely, and it happens for a structural reason: the diagnostic criteria used to identify IBS do not include any testing for bacterial overgrowth. The Rome IV criteria, which define IBS, are based entirely on symptom patterns. A patient who has bloating, abdominal pain, and altered bowel habits for three months meets the criteria for IBS whether or not bacteria are overgrown in their small intestine. No breath test is required. No aspirate culture is ordered. The IBS label is applied, and the investigation stops. For the estimated 60-78% of IBS patients who actually have SIBO, this means the treatable cause of their symptoms goes unidentified.
Why does SIBO get misdiagnosed as IBS?
The misdiagnosis happens because of how IBS is defined, not because of physician negligence. The Rome IV criteria were designed to give clinicians a positive diagnostic framework for functional GI disorders, so that IBS could be identified based on symptom patterns rather than requiring exhaustive testing to rule out every possible organic cause. This was a well-intentioned advance in gastroenterology. The problem is that SIBO produces symptoms identical to IBS, and the Rome IV framework does not account for this overlap.
The standard IBS diagnostic workup typically includes a complete blood count, C-reactive protein or ESR to screen for inflammation, celiac serology (tissue transglutaminase antibodies), and sometimes a colonoscopy to rule out inflammatory bowel disease or colorectal pathology. These tests are appropriate for excluding dangerous conditions. But SIBO is not on the exclusion list. Breath testing is not part of the algorithm. A patient can pass through the entire IBS diagnostic workup with active bacterial overgrowth in their small intestine, and no test in the standard panel will catch it.
How big is the diagnostic gap?
The numbers are striking. In a landmark study by Pimentel and colleagues published in 2000, 78% of patients meeting Rome criteria for IBS tested positive for SIBO on lactulose breath testing. A systematic review by Lin in 2004 found SIBO prevalence rates of 60-84% across studies of IBS patients. Even more conservative estimates using the glucose breath test (which has lower sensitivity) find SIBO rates of 30-40% in IBS populations.
These are not small numbers. They suggest that a substantial majority of people carrying an IBS diagnosis may have a treatable bacterial overgrowth that has never been evaluated. The gap exists not because the tests are unavailable but because the standard clinical pathway does not include them.
âšī¸The 2020 ACG Clinical Guideline on SIBO acknowledges the overlap between IBS and SIBO but stops short of recommending routine SIBO screening for all IBS patients. The guideline recommends breath testing when SIBO is clinically suspected, based on risk factors and symptom patterns.
What clinical scenarios lead to misdiagnosis?
Certain patterns recur in patients whose SIBO is missed and labeled as IBS. Recognizing these scenarios can help patients and clinicians identify when further testing is needed.
- The post-food-poisoning patient. A previously healthy person develops acute gastroenteritis. The acute infection resolves, but chronic bloating, diarrhea, and pain develop over the following weeks to months. They see their doctor, meet Rome IV criteria, and receive an IBS-D diagnosis. The underlying mechanism, autoimmune damage to the migrating motor complex from CdtB toxin, is never investigated. Breath testing and anti-vinculin antibody testing would identify the SIBO and its cause.
- The low-FODMAP partial responder. A patient with IBS starts a low-FODMAP diet and gets partial improvement. This is interpreted as confirmation that IBS was the correct diagnosis. However, a low-FODMAP diet also reduces symptoms of SIBO by starving the overgrown bacteria. The partial response is consistent with both conditions, and the underlying bacterial overgrowth remains untreated.
- The PPI user with new GI symptoms. A patient on long-term proton pump inhibitors for acid reflux develops bloating, gas, and loose stools. These are attributed to IBS or medication side effects. In reality, PPIs reduce gastric acid, one of the body's primary defenses against bacterial overgrowth in the small intestine. A meta-analysis by Lo and Chan (2013) found that PPI use increases SIBO risk significantly.
- The patient with normal colonoscopy. After negative celiac bloodwork and a normal colonoscopy, the gastroenterologist confirms IBS. The patient is told there is nothing structurally wrong. This is accurate in terms of what was tested, but SIBO is not visible on colonoscopy and is not detected by celiac panels. The normal results create false reassurance.
- The opioid or anticholinergic user. Patients taking medications that slow gut motility (opioids for chronic pain, anticholinergic medications for overactive bladder or allergies) are at elevated risk for SIBO because reduced motility impairs the MMC's ability to clear bacteria from the small intestine. Their GI symptoms are often attributed to medication side effects or coincidental IBS rather than secondary SIBO.
Who is most at risk for SIBO being missed?
Several patient populations face higher risk of having SIBO misclassified as IBS. These include people with a documented history of food poisoning or travelers' diarrhea, patients on PPIs for more than 12 months, people taking opioids or anticholinergic medications regularly, patients with hypothyroidism (which slows gut motility), people with a history of abdominal surgery (particularly involving the ileocecal valve), patients with diabetes mellitus (autonomic neuropathy impairs gut motility), and people with connective tissue disorders like Ehlers-Danlos syndrome (associated with structural and motility abnormalities). If you fall into any of these categories and carry an IBS diagnosis, the probability that SIBO is contributing to your symptoms increases substantially.
What to ask your doctor
If you suspect your IBS may actually be SIBO, or that SIBO may be contributing to symptoms that are not responding to IBS treatments, there are specific questions and requests that can move the conversation forward productively.
- "I have been diagnosed with IBS but my symptoms are not improving with current treatments. Can we test for SIBO with a lactulose breath test?" This is a direct, reasonable request. Most gastroenterologists can order this test, and many labs (including trio-smart through Gemelli Biotech) offer at-home kits.
- "My symptoms started after a bout of food poisoning. Could this be post-infectious IBS with underlying SIBO? Would the ibs-smart antibody test be appropriate?" This gives your doctor specific clinical context and names the relevant diagnostic tool.
- "I notice my bloating gets significantly worse within an hour of eating and improves when I skip meals. Is this pattern consistent with SIBO?" Describing the temporal relationship between eating and symptoms helps the clinician assess whether SIBO testing is clinically indicated.
- "I have been on a PPI for more than a year. Could that be contributing to bacterial overgrowth in my small intestine?" This raises an evidence-based risk factor that your doctor should be able to evaluate.
- "If the breath test is negative, does that rule out SIBO completely, or should we consider the trio-smart test for hydrogen sulfide?" This shows you understand the limitations of standard testing and opens the door for more comprehensive evaluation.
â ī¸If your gastroenterologist dismisses SIBO testing without explanation, it is reasonable to seek a second opinion. SIBO is a recognized, evidence-based condition with validated diagnostics. Reluctance to test is not the same as evidence that you do not have it.
What happens after misdiagnosis is corrected?
When SIBO is identified in a patient previously diagnosed with IBS, the treatment approach shifts from symptom management to cause-directed therapy. Rifaximin (550 mg three times daily for 14 days) is the standard first-line treatment for hydrogen-dominant SIBO. For methane-dominant overgrowth (IMO), rifaximin is typically combined with neomycin or metronidazole. Herbal antimicrobial protocols are an alternative for patients who cannot access or tolerate rifaximin. After eradication, prokinetic therapy to restore MMC function is often critical for preventing recurrence.
For many patients, correcting the diagnosis is the turning point. Studies show that eradicating SIBO leads to significant symptom improvement in a majority of patients who previously failed IBS treatments. The Pimentel 2000 study found that 48% of patients who normalized their breath test had complete resolution of IBS symptoms. Even partial responders often report meaningful improvement in bloating, pain, and bowel regularity.
Frequently Asked Questions
How common is it for SIBO to be misdiagnosed as IBS?
Very common. Studies consistently find that 60-78% of patients meeting IBS criteria test positive for SIBO when breath testing is performed. Because breath testing is not part of the standard IBS diagnostic workup, most of these cases go unidentified unless a clinician specifically suspects and tests for SIBO.
Can my primary care doctor test for SIBO, or do I need a specialist?
Primary care physicians can order SIBO breath tests, and at-home test kits (like trio-smart) make this accessible without a specialist visit. However, interpreting results and managing treatment may benefit from a gastroenterologist or a physician experienced in SIBO management. If your primary care doctor is unfamiliar with SIBO testing, a referral to GI is reasonable.
Does a normal colonoscopy rule out SIBO?
No. Colonoscopy examines the large intestine and cannot detect bacterial overgrowth in the small intestine. SIBO does not cause visible structural changes that colonoscopy can identify. A normal colonoscopy rules out inflammatory bowel disease, polyps, and colorectal cancer, but it says nothing about SIBO.
If I respond to a low-FODMAP diet, does that mean I have IBS and not SIBO?
Not necessarily. A low-FODMAP diet reduces symptoms of both IBS and SIBO because it limits the fermentable carbohydrates that overgrown bacteria feed on. Partial improvement on a low-FODMAP diet is actually consistent with SIBO. If you improve on low-FODMAP but cannot reintroduce foods without symptoms returning, SIBO testing is warranted.
How long does it typically take to get a correct SIBO diagnosis?
Published data on average diagnostic delay for SIBO specifically is limited. However, patient surveys and clinical experience suggest that many SIBO patients spend 2-5 years receiving IBS treatment before SIBO is identified. The delay is driven by the absence of SIBO testing in standard IBS protocols, not by diagnostic difficulty once the test is ordered.
â ī¸This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.